ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase 2 multicentre, open‐label feasibility trial
British Journal of Dermatology
◽
10.1111/bjd.20782
◽
2021
◽
Author(s):
M. Goebeler
◽
Z. Bata‐Csörgő
◽
C. De Simone
◽
B. Didona
◽
E. Remenyik
◽
...
Keyword(s):
Pemphigus Vulgaris
◽
Fc Receptor
◽
Feasibility Trial
◽
Phase 2
◽
Neonatal Fc Receptor
◽
Open Label
◽
Receptor Inhibitor
Get full-text (via PubEx)
Related Documents
Cited By
References
LB773 Treating pemphigus vulgaris (PV) and foliaceus (PF) by inhibiting the neonatal Fc receptor: Phase 2 multicentre open-label trial with efgartigimod
Journal of Investigative Dermatology
◽
10.1016/j.jid.2021.07.039
◽
2021
◽
Vol 141
(9)
◽
pp. B16
Author(s):
M. Goebeler
◽
Z. Bata-Csörgo
◽
C. de Simone
◽
B. Didona
◽
E. Remenyik
◽
...
Keyword(s):
Pemphigus Vulgaris
◽
Fc Receptor
◽
Phase 2
◽
Neonatal Fc Receptor
◽
Open Label
◽
Open Label Trial
◽
Receptor Phase
Get full-text (via PubEx)
Efgartigimod alfa. Neonatal Fc receptor (FcRn) antagonist, Treatment of generalized myasthenia gravis, Treatment of primary immune thrombocytopenia, Treatment of pemphigus vulgaris and foliaceous, Treatment of chronic inflammatory demyelinating polyneuropathy
Drugs of the Future
◽
10.1358/dof.2021.46.9.3325408
◽
2021
◽
Vol 46
(9)
◽
pp. 691
Author(s):
D. Ribeiro
Keyword(s):
Myasthenia Gravis
◽
Immune Thrombocytopenia
◽
Chronic Inflammatory Demyelinating Polyneuropathy
◽
Pemphigus Vulgaris
◽
Fc Receptor
◽
Demyelinating Polyneuropathy
◽
Neonatal Fc Receptor
◽
Inflammatory Demyelinating Polyneuropathy
◽
Primary Immune Thrombocytopenia
Get full-text (via PubEx)
Critical Role of the Neonatal Fc Receptor (FcRn) in the Pathogenic Action of Antimitochondrial Autoantibodies Synergizing with Anti-desmoglein Autoantibodies in Pemphigus Vulgaris
Journal of Biological Chemistry
◽
10.1074/jbc.m115.668061
◽
2015
◽
Vol 290
(39)
◽
pp. 23826-23837
◽
Cited By ~ 28
Author(s):
Yumay Chen
◽
Alex Chernyavsky
◽
Robert J. Webber
◽
Sergei A. Grando
◽
Ping H. Wang
Keyword(s):
Critical Role
◽
Pemphigus Vulgaris
◽
Fc Receptor
◽
Neonatal Fc Receptor
◽
Pathogenic Action
Get full-text (via PubEx)
035 Humanized anti-Desmoglein-3 antibodies as tools for research on the role of the neonatal Fc receptor in pemphigus vulgaris
Journal of Investigative Dermatology
◽
10.1016/j.jid.2021.08.036
◽
2021
◽
Vol 141
(10)
◽
pp. S154
Author(s):
A. Zakrzewicz
◽
C. Würth
◽
B. Beckert
◽
S. Feldhoff
◽
P. Verheesen
◽
...
Keyword(s):
Pemphigus Vulgaris
◽
Fc Receptor
◽
Neonatal Fc Receptor
◽
Desmoglein 3
Get full-text (via PubEx)
Humanized anti-Desmoglein-3 antibodies as tools for research on the role of the neonatal Fc receptor in pemphigus vulgaris
10.26226/morressier.61081ff8bc981037240fe3ab
◽
2021
◽
Author(s):
Ritva Tikkanen
Keyword(s):
Pemphigus Vulgaris
◽
Fc Receptor
◽
Neonatal Fc Receptor
◽
Desmoglein 3
Get full-text (via PubEx)
Decision letter for "Interim Analysis of a Phase 2 Open‐Label Trial Assessing Burosumab Efficacy and Safety in Patients With Tumor‐Induced Osteomalacia"
10.1002/jbmr.4184/v1/decision1
◽
2020
◽
Keyword(s):
Interim Analysis
◽
Phase 2
◽
Efficacy And Safety
◽
Open Label
Get full-text (via PubEx)
Review for "Interim Analysis of a Phase 2 Open‐Label Trial Assessing Burosumab Efficacy and Safety in Patients With Tumor‐Induced Osteomalacia"
10.1002/jbmr.4184/v2/review2
◽
2020
◽
Keyword(s):
Interim Analysis
◽
Phase 2
◽
Efficacy And Safety
◽
Open Label
Get full-text (via PubEx)
Efficacy, Health-Related Outcomes, and Safety of Ixekizumamb for up to Five Years of Open-Label Treatment in a Phase 2 Study in Chronic Plaque Psoriasis
SKIN The Journal of Cutaneous Medicine
◽
10.25251/skin.1.supp.11
◽
2017
◽
Vol 1
◽
pp. s12
Author(s):
Andrew Blauvelt
◽
Craig Leonardi
◽
Claus Zachariae
◽
Russel Burge
◽
Terri Ridenour
◽
...
Keyword(s):
Plaque Psoriasis
◽
Phase 2
◽
Chronic Plaque Psoriasis
◽
Open Label
◽
Phase 2 Study
◽
Health Related
Abstract Not Available
Get full-text (via PubEx)
Orphan designation: Anti-neonatal Fc receptor human monoclonal antibody, Prevention of haemolytic disease of the foetus and newborn
Case Medical Research
◽
10.31525/cmr-277ad45
◽
2020
◽
Author(s):
Keyword(s):
Monoclonal Antibody
◽
Human Monoclonal Antibody
◽
Fc Receptor
◽
Neonatal Fc Receptor
◽
Haemolytic Disease
◽
Orphan Designation
Get full-text (via PubEx)
A Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension
Case Medical Research
◽
10.31525/ct1-nct04257929
◽
2020
◽
Author(s):
Keyword(s):
Prader Willi Syndrome
◽
Phase 2
◽
Open Label
◽
Safety And Efficacy
◽
Phase 2 Study
◽
Open Label Extension
Get full-text (via PubEx)
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close